Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page


My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1966 2
1967 2
1969 2
1970 1
1971 1
1972 1
1973 2
1974 9
1975 5
1976 1
1977 2
1978 2
1979 1
1982 1
1985 1
1990 1
1991 1
1993 1
1995 1
1996 3
1997 8
1998 2
1999 2
2000 3
2001 4
2002 5
2003 4
2004 4
2005 1
2006 1
2007 1
2008 5
2009 4
2010 6
2011 8
2012 8
2013 8
2014 5
2015 7
2016 4
2017 6
2018 5
2019 8
2020 5
2021 10
2022 13
2023 9
2024 6

Text availability

Article attribute

Article type

Publication date

Search Results

176 results

Results by year

Filters applied: . Clear all
Page 1
Discovery of amivantamab (JNJ-61186372), a bispecific antibody targeting EGFR and MET.
Neijssen J, Cardoso RMF, Chevalier KM, Wiegman L, Valerius T, Anderson GM, Moores SL, Schuurman J, Parren PWHI, Strohl WR, Chiu ML. Neijssen J, et al. Among authors: valerius t. J Biol Chem. 2021 Jan-Jun;296:100641. doi: 10.1016/j.jbc.2021.100641. Epub 2021 Apr 8. J Biol Chem. 2021. PMID: 33839159 Free PMC article.
Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors.
de Weers M, Tai YT, van der Veer MS, Bakker JM, Vink T, Jacobs DC, Oomen LA, Peipp M, Valerius T, Slootstra JW, Mutis T, Bleeker WK, Anderson KC, Lokhorst HM, van de Winkel JG, Parren PW. de Weers M, et al. Among authors: valerius t. J Immunol. 2011 Feb 1;186(3):1840-8. doi: 10.4049/jimmunol.1003032. Epub 2010 Dec 27. J Immunol. 2011. PMID: 21187443 Clinical Trial.
Bispecific Complement Engagers for Targeted Complement Activation.
Pedersen DV, Gytz H, Winkler MBL, Zarantonello A, Baumann N, Hansen AG, Thiel S, Andersen GR, Valerius T, Laursen NS. Pedersen DV, et al. Among authors: valerius t. J Immunol. 2023 Aug 1;211(3):403-413. doi: 10.4049/jimmunol.2200952. J Immunol. 2023. PMID: 37350633
Antibody Isotypes for Tumor Immunotherapy.
Kretschmer A, Schwanbeck R, Valerius T, Rösner T. Kretschmer A, et al. Among authors: valerius t. Transfus Med Hemother. 2017 Sep;44(5):320-326. doi: 10.1159/000479240. Epub 2017 Sep 7. Transfus Med Hemother. 2017. PMID: 29070977 Free PMC article. Review.
Complement in antibody-based tumor therapy.
Derer S, Beurskens FJ, Rosner T, Peipp M, Valerius T. Derer S, et al. Among authors: valerius t. Crit Rev Immunol. 2014;34(3):199-214. doi: 10.1615/critrevimmunol.2014009761. Crit Rev Immunol. 2014. PMID: 24941073 Review.
Disruption of the sialic acid/Siglec-9 axis improves antibody-mediated neutrophil cytotoxicity towards tumor cells.
Lustig M, Chan C, Jansen JHM, Bräutigam M, Kölling MA, Gehlert CL, Baumann N, Mester S, Foss S, Andersen JT, Bastian L, Sondermann P, Peipp M, Burger R, Leusen JHW, Valerius T. Lustig M, et al. Among authors: valerius t. Front Immunol. 2023 Jun 6;14:1178817. doi: 10.3389/fimmu.2023.1178817. eCollection 2023. Front Immunol. 2023. PMID: 37346044 Free PMC article.
IgA antibody immunotherapy targeting GD2 is effective in preclinical neuroblastoma models.
Stip MC, Evers M, Nederend M, Chan C, Reiding KR, Damen MJ, Heck AJR, Koustoulidou S, Ramakers R, Krijger GC, de Roos R, Souteyrand E, Cornel AM, Dierselhuis MP, Jansen M, de Boer M, Valerius T, van Tetering G, Leusen JHW, Meyer-Wentrup F. Stip MC, et al. Among authors: valerius t. J Immunother Cancer. 2023 Jul;11(7):e006948. doi: 10.1136/jitc-2023-006948. J Immunother Cancer. 2023. PMID: 37479484 Free PMC article.
Myeloid checkpoint blockade improves killing of T-acute lymphoblastic leukemia cells by an IgA2 variant of daratumumab.
Baumann N, Arndt C, Petersen J, Lustig M, Rösner T, Klausz K, Kellner C, Bultmann M, Bastian L, Vogiatzi F, Leusen JHW, Burger R, Schewe DM, Peipp M, Valerius T. Baumann N, et al. Among authors: valerius t. Front Immunol. 2022 Aug 16;13:949140. doi: 10.3389/fimmu.2022.949140. eCollection 2022. Front Immunol. 2022. PMID: 36052078 Free PMC article.
Organ-on-a-chip models for development of cancer immunotherapies.
Chernyavska M, Masoudnia M, Valerius T, Verdurmen WPR. Chernyavska M, et al. Among authors: valerius t. Cancer Immunol Immunother. 2023 Dec;72(12):3971-3983. doi: 10.1007/s00262-023-03572-7. Epub 2023 Nov 3. Cancer Immunol Immunother. 2023. PMID: 37923890 Free PMC article. Review.
Engineered CD3 antibodies for immunosuppression.
Renders L, Valerius T. Renders L, et al. Among authors: valerius t. Clin Exp Immunol. 2003 Sep;133(3):307-9. doi: 10.1046/j.1365-2249.2003.02227.x. Clin Exp Immunol. 2003. PMID: 12930354 Free PMC article. Review. No abstract available.
176 results